Feb 7, 2020 by David HaenIs This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.
Feb 7, 2020 by David Haen3 Canadian Biotechs to Consider Buying TodayThese developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.
Feb 6, 2020 by David HaenHow Did Last Week's IPOs Perform?These four companies just made their debuts. Should they be on your radar?
Feb 4, 2020 by David HaenIs Acceleron Pharma Stock a Buy?The stock's price surged following a clinical trial success, but should investors now temper their enthusiasm?
Jan 30, 2020 by David HaenWhere Will Exact Sciences Be in 5 Years?This developer of diagnostic tests will continue to drive the personalization of cancer treatment.
Jan 29, 2020 by David HaenBetter Buy: Align Technology Vs. EnvistaThese two dental products companies battle for investors’ attention. Which stock is more attractive?
Jan 24, 2020 by David HaenDouble Your Money with This BiotechWith its first FDA approval in hand, a second, more lucrative indication looms on the horizon.
Jan 23, 2020 by David HaenBetter Buy: Exact Sciences vs. QiagenOne just wrapped up a multi-billion-dollar acquisition while the other elected to remain independent.
Jan 23, 2020 by David HaenWhere Will Intercept Pharmaceuticals Be in 5 Years?Intercept's chances of remaining independent over the long-term are slim.
Jan 23, 2020 by David HaenWhat Company Will Eli Lilly Buy Next?Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
Jan 19, 2020 by David Haen2 Biotechs Battling Immune DiseasesDuking it out in two immune-related diseases, these biotechs couldn’t be more different.
Jan 18, 2020 by David HaenWhat Does the Future Hold for Nextcure?Nextcure's solid footing should sustain it despite Eli Lilly's decision to walk away from an R&D pact.
Jan 16, 2020 by David HaenWill Bruker’s Stock Keep Climbing?A track record of delivering innovative products continues to drive this company forward.
Jan 15, 2020 by David HaenWhy You Should Own This Medical Device Company in 2020A recent stock price dip gives buy-and-hold investors an attractive entry price.
Jan 14, 2020 by David HaenWill Theravance Biopharma Finally Break Out in 2020?Despite achieving several milestones over the past two years, the stock’s response has been muted.
Jan 12, 2020 by David Haen2 Health Tech Companies Set to Beat Earnings EstimatesPositive industry trends should benefit these companies.
Jan 7, 2020 by David HaenWhere Will GW Pharmaceuticals Be in 5 Years?This frontrunner in cannabinoid research will continue to thrive.
Jan 7, 2020 by David HaenBetter Buy: Geron vs. IncyteFormed in the early ‘90s, Geron and Incyte exemplify the long and often tumultuous road it takes to translate science into medicines.
Jan 5, 2020 by David HaenIs Intellia Therapeutics Stock a Buy?Its CRISPR technology has the potential to cure certain genetic diseases, but investors who buy in now will require patience.
Jan 4, 2020 by David Haen3 Top Biotech Stocks to Buy in JanuaryThese companies could kick off the year with big announcements and deliver gains to savvy investors.
